Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer.
Prostate cancer is an excellent target for an active vaccine-based approach based on the fact that prostate cancer cells express unique proteins which serve as highly specific targets. APC8015 (Provenge) is one such investigational therapeutic vaccine that uses autologous antigen presenting cells (APCs) loaded with a recombinant fusion protein of prostatic acid phosphatase linked to a molecule that specifically targets a receptor expressed on the surface of human APCs. Clinical trial outcomes have demonstrated activity in patients with androgen independent prostate cancer.
Schellhammer
Paul F
PF
Eastern Virginia Medical School and Devine Tidewater Urology, Norfolk, VA 23502, USA. schellpf@evms.edu
Hershberg
Robert M
RM
D000135:Acid Phosphatase; D000728:Androgens / Q000378:metabolism*; D001324:Autoantigens / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000627:therapeutic use; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D017027:Protein Tyrosine Phosphatases / Q000378:metabolism; D013601:T-Lymphocytes / Q000276:immunology; D016896:Treatment Outcome
D000728:Androgens; D001324:Autoantigens; D019496:Cancer Vaccines; D000135:Acid Phosphatase; C428439:prostatic acid phosphatase; D017027:Protein Tyrosine Phosphatases